Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra - Summary - MDSpire

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra

  • By

  • Shirkhan Amikishiyev

  • Rabia Deniz

  • Mehmet Guven Gunver

  • Sarvan Aghamuradov

  • Nevzat Koca

  • Burak Ince

  • Murat Bektas

  • Aysenur Yilmaz

  • Yagmur Canturk

  • Gorkem Durak

  • Murat Kose

  • Mustafa Erelel

  • Arif Atahan Çağatay

  • Serap Simsek Yavuz

  • Sevgi Kalayoglu Besisik

  • Figen Esen

  • Ahmet Gül

  • May 22, 2026

  • 0 min

Share

Objective:

To evaluate the performance of the Hyperinflammation in COVID-19 (HIC) score as a diagnostic and dynamic monitoring tool for treatment response and prognosis in patients treated with anakinra.

Key Findings:
  • Overall mortality was 12.8%.
  • Survivors had a faster CRP reduction (3.1 days) compared to non-survivors (4.7 days).
  • Divergence in ΔHIC and other inflammatory parameters was observed within 3–4 days.
  • HIC scores at the initiation of anakinra and at final assessment effectively discriminated between survivors and non-survivors (AUC 0.75, p < 0.001).
  • Baseline and first-response-day HIC scores had limited predictive value (AUC approximately 0.50–0.55).
Interpretation:

Limitations:
  • The study was limited to patients treated with anakinra, which may affect generalizability.
  • Retrospective design may introduce biases.
Conclusion:

Original Source(s)

Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: application to a large series of patients receiving anakinra

  • by Shirkhan Amikishiyev, Rabia Deniz, Mehmet Guven Gunver, Sarvan Aghamuradov, Nevzat Koca, Burak Ince, Murat Bektas, Aysenur Yilmaz, Yagmur Canturk, Gorkem Durak, Murat Kose, Mustafa Erelel, Arif Atahan Çağatay, Serap Simsek Yavuz, Sevgi Kalayoglu Besisik, Figen Esen, Ahmet Gül

  • May 22, 2026

Related Content

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Assessing PEPFAR’s Health Spillover Effects Beyond HIV: An Update